Antisense oligonucleotide (ASO)
Ended Awarded Last action
- Contract number
- 75N95A22F00002
- Awardee
-
Integrated DNA Technologies, Inc. UEI P55FTN1UMYZ1
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $13,406
Award facts
- Contract value 100% obligated
- $13,406.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325199 All Other Basic Organic Chemical Manufacturing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Coralville, IA 52241, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $13,406 |
About this award
Integrated DNA Technologies, Inc. (IDT), headquartered in Coralville, Iowa, received a Blanket Purchase Agreement (BPA) call award from the National Institute of Neurological Disorders and Stroke (NINDS) on August 17, 2022, with a ceiling value of $13,406.24. This Firm Fixed Price contract is for antisense oligonucleotide (ASO) products and was completed by May 31, 2023. The award was made without a set-aside designation, demonstrating IDT's competitive standing in open market procurements. IDT is a leading manufacturer of specialized nucleic acid products and services, including custom DNA and RNA oligonucleotides, gene fragments, sequencing products, and other molecular biology reagents essential for biomedical research.
This BPA call represents work under IDT's larger $10 million Blanket Purchase Agreement with NINDS, which enables the company to provide custom oligonucleotides, DNA and RNA synthesis services, gene fragments, sequencing products, and specialized reagents to support the institute's research initiatives. NINDS, part of the National Institutes of Health, focuses on research related to neurological disorders and neuroscience. IDT's provision of antisense oligonucleotides supports critical research applications in neurotoxicity studies and genetic research relevant to NINDS's mission. As a parent corporate entity registered in SAM.gov since 2001, IDT has maintained a robust portfolio of federal contract vehicles across multiple agencies, including the Department of Defense, Centers for Disease Control and Prevention, and Department of Veterans Affairs.
Quick answers
Who was awarded contract 75N95A22F00002?
75N95A22F00002 was awarded to Integrated DNA Technologies, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on August 17, 2022.
How much is contract 75N95A22F00002 worth?
The government has obligated $13,406 on 75N95A22F00002.
Is contract 75N95A22F00002 an order under another contract?
Yes. 75N95A22F00002 is a BPA call under HHSN263201500214B, a blanket purchase agreement.
Was contract 75N95A22F00002 competed?
The extent of competition for 75N95A22F00002 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award